This contract expires in 475 days (Sep 30, 2027).
THE EMMES COMPANY, LLC - INTEGRATED CARE AND TREATMENT FOR SEVERE INFECTIOUS DISEASES AND SUBSTANCE USE DISORDERS (SUD) AMONG HOSPITALIZED PATIENTS (CTN-0121). 09/28/2022 - 02/07/2026. DSC6. 75N95022F00002 (TO2).
Key Details
Description
INTEGRATED CARE AND TREATMENT FOR SEVERE INFECTIOUS DISEASES AND SUBSTANCE USE DISORDERS (SUD) AMONG HOSPITALIZED PATIENTS (CTN-0121). 09/28/2022 - 02/07/2026. DSC6. 75N95022F00002 (TO2).
Context & Analysis
On Jan 27, 2026, Department of Health and Human Services obligated $2,067,729 to THE EMMES COMPANY, LLC for integrated care and treatment for severe infectious diseases and substance use disorders (sud) among hospitalized patients (ctn-0121). 09/28/2022 - 02/07/2026. dsc6. 75n95022f00002 (to2).. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition. Performance is located in ROCKVILLE, MD. The contract is scheduled through Sep 30, 2027 — approximately 16 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.
Contractor Information
Similar Awards
NCI OPERATIONAL TASK ORDER, FY26-FY27
LEIDOS BIOMEDICAL RESEARCH INC
$327.1M
MD NET
LEIDOS BIOMEDICAL RESEARCH INC
$163.5M
ADVANCE UNIVERSAL INFLUENZA VACCINE - FLU MOSAIC VERSION 2 (FLUMOSV2)
LEIDOS BIOMEDICAL RESEARCH INC
$141.7M
AWARD OF THE BASE TO ST. JUDE FOR CEIRR CONTRACT 75N93021C00016. THIS CONTRACT WILL SUPPORT NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (CEIRR).
ST JUDE CHILDREN'S RESEARCH HOSPITAL INC
$103.3M
DOMESTIC INDUSTRIAL BASE EXPANSION OF KEY CHEMICALS FOR ACRYLONITRILE BUTADIENE RUBBER (NBR)
ASCEND PERFORMANCE MATERIALS TEXAS INC
$87.7M
Stay Updated
Get notified about new opportunities matching your interests.